tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Dermatomycoses D003881 17 associated lipids
Dermatomyositis D003882 2 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Digestive System Diseases D004066 3 associated lipids
Down Syndrome D004314 18 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Dyspnea D004417 10 associated lipids
Earache D004433 2 associated lipids
Echinostomiasis D004451 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Eczema D004485 4 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Epididymitis D004823 1 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Erythema D004890 22 associated lipids
Erythema Nodosum D004893 5 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Erythroplasia D004919 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Exanthema D005076 11 associated lipids
Eye Diseases D005128 12 associated lipids
Facial Dermatoses D005148 7 associated lipids
Facial Neoplasms D005153 3 associated lipids
Fatigue D005221 10 associated lipids
Fatty Liver D005234 48 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Folliculitis D005499 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Foot Dermatoses D005533 3 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Castleman Disease D005871 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Gingivitis D005891 3 associated lipids
Glioma D005910 112 associated lipids
Gliosis D005911 6 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Glycosuria D006029 10 associated lipids
Gout D006073 4 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Graves Disease D006111 6 associated lipids
Gynecomastia D006177 6 associated lipids
Hallucinations D006212 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Hand Injuries D006230 1 associated lipids
Headache D006261 4 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Heart Failure D006333 36 associated lipids
Heart Injuries D006335 6 associated lipids
Hematologic Diseases D006402 3 associated lipids
Hematoma D006406 5 associated lipids
Hematuria D006417 13 associated lipids
Hemolysis D006461 131 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Hemophilia A D006467 10 associated lipids
Hemorrhage D006470 15 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Hepatitis C D006526 7 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hernia, Ventral D006555 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Herpesviridae Infections D006566 4 associated lipids
HIV Seropositivity D006679 15 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hydronephrosis D006869 4 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperglycemia D006943 21 associated lipids
Hyperkalemia D006947 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Brown Z and Neild GH FK-506 and haemolytic uraemic syndrome. 1990 Lancet pmid:1689442
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Yamamoto K et al. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. 1990 Immunology pmid:1689694
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Suzuki N et al. Effects of a novel immunosuppressive agent, FK506, on human B cell activation. 1990 Clin. Exp. Immunol. pmid:1690097
McCauley J et al. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. 1990 Lancet pmid:1690326
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Woo J et al. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. 1990 Scand. J. Immunol. pmid:1690915
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Deguchi K et al. [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. 1990 No To Shinkei pmid:1697182
Murase N et al. Prevention of spontaneous diabetes in BB rats with FK 506. 1990 Lancet pmid:1697397
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Hara S et al. The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. 1990 Clin. Immunol. Immunopathol. pmid:1700936
Murase N et al. Effect of FK 506 on spontaneous diabetes in BB rats. 1990 Diabetes pmid:1700959
Kawashima H and Mochizuki M Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. 1990 Exp. Eye Res. pmid:1701148
Siekierka JJ et al. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. 1990 J. Biol. Chem. pmid:1701173
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Tsuji RF et al. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. 1990 J. Antibiot. pmid:1701765
Granelli-Piperno A et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. 1990 J. Exp. Med. pmid:1701825
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Arai K et al. Prolonged limb allograft survival with short-term treatment with FK-506 in rats. 1989 Transplant. Proc. pmid:2468256
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Hatanaka H et al. FK-506 related compounds produced by Streptomyces tsukubaensis No. 9993. 1989 J. Antibiot. pmid:2470720
Gschwendt M et al. The immunosuppressant FK-506, like cyclosporins and didemnin B, inhibits calmodulin-dependent phosphorylation of the elongation factor 2 in vitro and biological effects of the phorbol ester TPA on mouse skin in vivo. 1989 Immunobiology pmid:2471685
Fujii Y et al. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. 1989 Transplantation pmid:2472025
Tocci MJ et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. 1989 J. Immunol. pmid:2472451
Beck Y and Akiyama N Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. 1989 Transplant. Proc. pmid:2472695
Thomson AW FK-506--how much potential? 1989 Immunol. Today pmid:2473767
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Ochiai T et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. 1989 Transplantation pmid:2474209
Siekierka JJ et al. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. 1989 J. Immunol. pmid:2474605
Leonard DK et al. Toxicity of FK-506 in human fetal pancreas. 1989 Diabetes pmid:2463195
Stephen M et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. 1989 Transplantation pmid:2463701